Pregnant women unvaccinated against pertussis had infants with higher anti-PT IgG levels at six months
This prospective open-label controlled clinical trial examined the impact of immunization during pregnancy against pertussis on antibody responses in infants and their mothers. The study included 47 pregnant women who received a DTaP vaccine booster and 22 pregnant women who were not vaccinated. Their infants received hexavalent DTaP vaccine. The primary outcome assessed the effect of immunization during pregnancy on the epitopes and avidity of anti-pertussis toxin immunoglobulin G antibodies.
At six months of age, infants in the control group demonstrated higher anti-PT IgG concentrations compared to the vaccinated group. Additionally, higher epitope-specific inhibition targeting 1B7 and 11E6 was noted in the control group infants. The increase in avidity after vaccination was highest in those mothers and infants with lower baseline avidity.
No difference in avidity of anti-PT IgG was observed between the two study groups. The study did not report adverse events, discontinuations, or specific tolerability data. The authors did not provide p-values or confidence intervals for the avidity comparison or the baseline avidity increase finding. This trial suggests that infants of unvaccinated mothers may have higher antibody levels at six months than those exposed to maternal immunization.